BACKGROUND: Intrauterine devices have been gaining popularity for the past 2 decades. Current data report that >10% of women who use contraception are using an intrauterine device. With <1% failure rates, the intrauterine device is one of the most effective forms of long-acting reversible contraception, yet evidence shows that fear of pain during intrauterine device placement deters women from choosing an intrauterine device as their contraceptive method. OBJECTIVES: The objective of this analysis was to estimate the association between anticipated pain with intrauterine device placement and experienced pain. We also assessed other factors associated with increased discomfort during intrauterine device placement. We hypothesized that patients with higher levels of anticipated pain would report a higher level of discomfort during placement. STUDY DESIGN: We performed a secondary analysis of the Contraceptive CHOICE Project. There were 9256 patients enrolled in Contraceptive CHOICE Project from the St. Louis region from 2007e2011; data for 1149 subjects who came for their first placement of either the original 52-mg levonorgestrel intrauterine system or the copper intrauterine device were analyzed in this study. Patients were asked to report their anticipated pain before intrauterine device placement and experienced pain during placement on a 10-point visual analog scale. We assessed the association of anticipated pain, patient demographics, reproductive characteristics, and intrauterine device type with experienced pain with intrauterine device placement.
RESULTS:
The mean age of Contraceptive CHOICE Project participants in this subanalysis was 26 years. Of these 1149 study subjects, 44% were black, and 53% were of low socioeconomic status. The median expected pain score was 5 for both the levonorgestrel intrauterine system and the copper intrauterine device; the median experienced pain score was 5 for the levonorgestrel intrauterine system and 4 for the copper intrauterine device. After we controlled for parity, history of dysmenorrhea, and type of intrauterine device, higher anticipated pain was associated with increased experienced pain (adjusted relative risk for 1 unit increase in anticipated pain, 1.19; 95% confidence interval, 1.14e1.25). Nulliparity, history of dysmenorrhea, and the hormonal intrauterine device (compared with copper) also were associated with increased pain with intrauterine device placement. CONCLUSION: High levels of anticipated pain correlated with high levels of experienced pain during intrauterine device placement. Nulliparity and a history of dysmenorrhea were also associated with greater discomfort during placement. This information may help guide and treat patients as they consider intrauterine device placement. Future research should focus on interventions to reduce preprocedural anxiety and anticipated pain to potentially decrease discomfort with intrauterine device placement.
Key words: anticipated pain, discomfort, dysmenorrhea, nulliparity, pain, placement I ntrauterine devices (IUDs), including the copper (TCu830A) and the hormonal IUD (levonorgestrel intrauterine system [LNG-IUS]), are 2 of the most effective forms of reversible contraception available; failure rates are <1% for both perfect and typical use. 1 Multiple studies have demonstrated high levels of acceptability of IUDs and continuation rates at 2e3 years are in the range of 67e77%. 2, 3 In fact, continuation rates for IUDs are higher than those for shorter-acting reversible contraceptive methods, such as the pill, ring, contraceptive patch, or depomedroxyprogesterone acetate. 3 The rate of use of IUDs in the United States has increased steadily in the last 2 decades. The most recently published data demonstrates 10.3% of contracepting women aged 15e44 years are using an IUD. 4 Although the IUD is highly effective and acceptable, qualitative and anecdotal evidence has suggested that perceived pain with placement may be a barrier to the use of intrauterine contraception. 5 Few small studies have been published that have evaluated predictors of increased pain with IUD placement, and results have been inconsistent. Factors that have been associated with more significant pain at the time of IUD placement include nulliparity [6] [7] [8] [9] or no previous vaginal delivery, 10 age >30 years, 8 a longer interval since last pregnancy or menses, 7,8 a history of dysmenorrhea, 6 ,11 absence of current breastfeeding, 7, 8 and higher educational achievement. 7 Additionally, higher anxiety preceding the procedure or higher expected pain with placement has been associated with greater pain at the time of placement. 10, [12] [13] [14] Explaining the pros and cons of IUDs, guidance on what to expect during and after the procedure, and the suggestion of coping mechanisms like distraction techniques before placement have been proposed as methods to decrease pain with placement. 15 The purpose of this secondary analysis was to describe the pain or discomfort experienced with IUD placement and to assess whether anticipated or expected pain is associated with discomfort experienced with placement. We also sought to evaluate the association of demographic or psychological factors with increased pain with placement. Our Original Research ajog.org specific hypothesis was that subjects with higher levels of anticipated pain with placement would score higher on our scale of reported discomfort with placement.
Materials and Methods
We performed a secondary analysis of the women who underwent IUD placement in the Contraceptive CHOICE Project (CHOICE). CHOICE was a prospective cohort study that educated all participants about contraceptive methods, including the most effective methods (IUDs and the contraceptive implant). CHOICE reduced access obstacles to contraception and provided all methods at no cost. The goal of the study was to reduce the unintended pregnancy rate in the St. Louis, MO, region. 3 The methods of CHOICE have been described previously in this Journal 16 ; we will briefly outline the substudy methods here.
CHOICE project participants were 14e45 years old and were enrolled between August 2007 and September 2011. Inclusion criteria for CHOICE were as follows: (1) sexually active or planning to become sexually active with a male partner within the next 6 months, (2) willing to begin using or switch to a new reversible method of contraception, and (3) English or Spanish speaking. If individuals wanted to conceive in the next 12 months or had undergone a hysterectomy or sterilization procedure, they were not eligible to participate in CHOICE. Participants were eligible for this secondary analysis if they chose an IUD (the original 52-mg LNG-IUS [Bayer, Whippany, NJ] or copper) for their contraceptive method and had their expected and experienced pain assessed at the placement visit (questions regarding pain with placement were added November 2010). Our analysis included each participant once. If a woman had multiple IUD placements during her participation in CHOICE, only the first CHOICE placement was included in the dataset. We did not exclude women who previously had an IUD before CHOICE enrollment. The Washington University in St. Louis institutional review board approved the study protocol, and all participants provided written informed consent.
All subjects were asked to complete a baseline questionnaire. We collected comprehensive demographic and reproductive data and information regarding sexual activity, medical history, and surgical history. At the baseline interview, women were asked "During the past 12 months, on average, how often did you have pain or cramping during your period?" Women were categorized as having a history of dysmenorrhea if they answered "often" or "always"; participants who responded "sometimes" or "never" were considered our referent group. Patients were considered to have a history of depression and/or anxiety if they provided an affirmative response to the question, "Have you ever had depression/anxiety?"
In CHOICE, many different providers (eg, nurse practitioners, residents, fellows, and attending physicians) inserted IUDs; however, most procedures (>80%) were done by nurse practitioners. In the few minutes before placement of their chosen IUD, women were asked to describe the pain they anticipated to experience with the IUD placement on a 10-point visual analog scale (VAS). In the few minutes after placement, participants were asked to rate their actual experienced pain on the same scale. This information was collected by the same provider who placed the IUD and was recorded along with the type of IUD that was placed.
The primary outcome of this study was the patients' score of the level of actual pain that she experienced during the IUD placement. Pain experienced during the IUD placement was analyzed 2 ways: (1) as a continuous variable and (2) dichotomized into experienced pain <7 (low pain score) vs !7 (high pain score). We chose a value of 7 on the pain scale as a clinically meaningful value that would be understandable to providers who would be interpreting these data for clinical use.
We considered a participant to be of "low socioeconomic status" if they answered "yes" to either of the following questions: "Do you currently receive food stamps, WIC, welfare, and/or unemployment?" or "During the past 12 months, have you had trouble paying for transportation, housing, health care, medical care or medications, and/or food?" We did not use household income in our definition, because many adolescents were cohabitating with parents or guardians and could not provide accurate household income data.
Patient characteristics were summarized with the use of mean and standard deviation, median and range, or frequency and percentage, depending on data type. Student t test or chi-square test was used to compare the patient characteristics between 2 IUD types. Our primary exposure variable in this analysis was anticipated pain with IUD placement. When experienced pain was treated as a continuous variable, linear regression models were used to estimate the change in experienced pain with placement. When experienced pain was treated as a dichotomized variable, Poisson regression models with robust variance were used to estimate the relative risk for high pain. Demographic and reproductive characteristics and IUD type were evaluated for potential confounding effect in the association between anticipated and experienced pain. Confounding was defined as a >10% relative change in the association between anticipated and experienced pain with or without the potential confounding covariate in the model. Confounders were included in the final multivariable model. All the statistical analyses were performed using Stata software (version 11; Stata Corporation, College Station, TX). The significance level (alpha) was set at .05.
Results
Of the 9256 CHOICE participants, there were 4302 IUD placements. Of these placements, we collected information regarding anticipated and experienced pain in 1208 participants. Once we excluded multiple IUD placements, 1149 IUD first placements remained in our dataset. Experienced pain with IUD placement by the participant demographics and characteristics is shown in Table 2 . In our unadjusted analysis, the following factors were associated with increased risk of high pain score with IUD placement: young age (<20 years), nonblack race, single and/or never married, normal body mass index, having private or no insurance, nulliparity, having no history of unintended pregnancy or termination of pregnancy, history of dysmenorrhea, and higher anticipated pain score. Table 3 shows results of the multivariable model. Four characteristics were found to be associated significantly with the risk of a high pain score in our adjusted model: level of expected pain, parity, history of dysmenorrhea, and the type of IUD chosen. For each additional "point" of pain expected on the VAS, a woman was 19% more likely to experience high pain (score, !7) during placement (relative risk, 1.19). Increasing parity was associated with experiencing less pain with placement. Women who had the LNG-IUS placed were more likely to experience high pain compared with women who had the copper IUD placed (relative risk, 1.31; 95% confidence interval, 1.05e1.63). Women who reported a history of dysmenorrhea were also more likely to experience high pain (relative risk, 1.53; 95% confidence interval, 1.28e1.83). The results from the linear regression lead to the same conclusions (data not shown).
Comment
In our analysis of >1000 IUD placements, we found that women with higher levels of anticipated pain were more likely to experience increased discomfort during placement, which supports our hypothesis. We also noted that nulliparity, history of dysmenorrhea, and placement of the LNG-IUS, compared with the copper IUD, were associated with higher pain scores.
Our finding that increased anticipated pain was associated with increased experienced pain with IUD placement is consistent with previous publications. 10, [12] [13] [14] Although an explanation for this finding has not yet been noted in the literature, studies that involve other procedures, such as cystoscopy and urodynamic procedures, provide greater detail. [17] [18] [19] Shaw et al 19 conducted a qualitative study that focused on ajog.org
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patients' feelings about urodynamics procedures to isolate reasons that contribute to patients' emotional and physical discomfort throughout the procedures. By recording unstructured interviews, researchers recognized anxiety and fear of embarrassment as key components correlated with increased discomfort during procedures. Several patients reported experiencing less anxiety after having conversations unrelated to the procedure with nurses and physicians. Simple conversations with healthcare professionals can put patients at ease with the procedure at hand by reducing anxiety levels and, in turn, decreasing discomfort at the procedure. On the other hand, conversing extensively about the procedure has not been shown to reduce experienced discomfort. 17 Our finding that nulliparity is associated with increased risk of high pain during IUD placement is also consistent with findings reported elsewhere. [6] [7] [8] [9] [10] 14 In a case-control study of factors associated with severe pain with IUD placement, women with parity <3 were more likely to experience severe pain compared with women with higher parity. 7 Allen et al 10 reported that women with no previous vaginal delivery were more likely to have increased pain with IUD placement, regardless of whether they were nulliparous or had only delivered via cesarean delivery; this effect was still noted in women who had some degree of cervical dilation before cesarean delivery.
Other studies have found an increased risk for high pain score in women with a history of dysmenorrhea. 6, 11 Dysmenorrhea may be associated with changes in uterine blood flow and hypercontractility. 11, 20, 21 Women with severe dysmenorrhea have altered central nervous system responses to pain, differences in steroid hormone levels, and differ from women without dysmenorrhea in several immunologic factors. [22] [23] [24] These same factors may predispose to pain with IUD placement.
We noted that women who had LNG-IUS placed were significantly more likely to report a high pain score than women who chose the copper IUD. The diameter of the original 52-mg LNG-IUS inserter tube (which was the only hormonal LNG-IUS used in CHOICE) was 4.8 mm at the time CHOICE IUD placements took place 25 ; the copper IUD insertion tube was 4.39AE0.1 mm (Teva Pharmaceuticals, personal communication). In 2012, after CHOICE recruitment was complete, the original 52-mg LNG-IUS inserter became 4.4 mm. Studies of IUD type and discomfort with placement have been mixed. One 2015 study that used the 4.8-mm inserter agreed with our findings.
14 Two other studies found no difference in pain with LNG-IUS vs copper IUD placement. 6, 11 Of these 2 studies, Kaislasuo et al 11 compared the copper IUD inserter tube to both the 4.8-mm and 4.4-mm LNG-IUS inserter, and Weibe 6 reported on placements that took place in 2013 (after the new inserter had been introduced) but did not specify the size of the tube that was used.
One previous study found that women >30 years old were more likely to experience high pain with IUD placement. 8 However, we found no relationship between age and experienced pain, even when we analyzed age as a continuous or categoric variable. Similarly, we found no association between level of education and experienced pain, which differs from one other report. 7 Several trials have attempted to identify methods for reducing pain with the IUD placement procedure. A Cochrane review published in 2015 and several subsequent trials have demonstrated some modest benefit in decreasing pain with lidocaine 4% topical gel in nulliparous women, lidocaine 10% spray in parous women, lidocaine 1% paracervical block, and a combined lidocaine-prilocaine cream. [26] [27] [28] [29] [30] [31] Tramadol and naproxen, but not ibuprofen, have been shown to have a modest effect on reducing pain with placement in parous women or within a short timeframe after placement for nulliparous women 28, 32 ; neither diclofenac nor ketorolac have shown clinical significance in pain reduction. 33, 34 Various studies have reported misoprostol use before IUD placement. A metaanalysis of most published data on misoprostol indicates that misoprostol is associated with no improvement in pain and occasionally in increased pain and unpleasant side-effects. 28 Only 1 study has shown misoprostol to decrease pain with IUD placement. 35 Studies of nitric oxide donors (in the forms of nitroprusside gel, nitroglycerin ointment, and inhaled N 2 O/O 2 ) have all shown no improvement in pain with placement. [36] [37] [38] Use of a vulsellum instead of a single-toothed tenaculum also does not appear to reduce pain that is experienced. 14 One strength of the analysis presented here is the large sample size of IUD Original Research GYNECOLOGY ajog.org placements with prospective data collection of anticipated and experienced pain. As a prospective cohort study, CHOICE was able to reduce the possibility of recall bias because data regarding anticipated and actual pain were collected in real time. One limitation of the data presented here is the limited details regarding any interventions that were used by clinicians and CHOICE participants at the time of IUD placement. Nonsteroidal antiinflammatory drugs routinely were offered to participants before IUD placement, and almost all women accepted this premedication. Lidocaine was used rarely for IUD placement in CHOICE and was reserved for more difficult insertions. Unfortunately, information regarding nonsteroidal antiinflammatory drug and lidocaine use was not collected routinely. We do not believe this has an appreciable impact on our results, given routine use of nonsteroidal antiinflammatory drugs and the very rare use of lidocaine. Given the recruitment years of the CHOICE study (2007e2011), we are not able to address pain with placement for other IUDs, such as LNG-IUS devices that are smaller or have a different dose of levonorgestrel or a different inserter. All participants were from a single, large midwestern city in the United States, and this population may not be generalizable to the US population. In summary, we found that higher anticipated pain was associated with discomfort experienced during IUD placement. In addition, nulliparity, a history of dysmenorrhea, and placement of the hormonal IUD (with a 4.8-mm inserter) were associated with higher placement pain scores. Our data may allow providers the opportunity to personalize their approach to IUD placement with appropriate, risk factorebased counseling before placement of an IUD. For example, a nulliparous patient with a history of dysmenorrhea and high anticipated pain or anxiety may benefit from additional patient-tailored counseling and the offer of evidence-based options for pain control. Researchers should focus future studies on interventions to reduce preprocedural anxiety and anticipated pain, with a goal of decreasing discomfort with IUD placement. n
